The CMV inSIGHT™ T Cell Immunity Panel measures the strength of T cell responses to Cytomegalovirus (CMV) specific antigens. It evaluates and reports the activity of CD4 and CD8 T cell responses independently. Effective T cell immunity against CMV is a factor in controlling CMV viral latency. CMV can affect patients with weakened immune systems and is a common risk factor in patients following solid organ or hematopoietic stem cell transplant.
Specimen Sources
Blood, ArterialBlood, CapillaryBlood, Central LineBlood, Venous
Specimen Types
Blood
Container
Dark Green
Collection Instructions
Container/Tube: Dark Green Sodium Heparin Tube Specimen: 10 mL whole Blood( tube must be 3/4 full (7.5mLmin ) to maintain proper ratio of blood to anticoagulant. Transport Temperature; Room Temperature ONLY Pediatric Patients: Whole Blood 4 mL min volume.
Note : Blood must be drawn Monday through Friday. DO NOT SHIP on days when a holiday follows within 2 days of the shipping day. Ship samples priority overnight Monday through Friday, at ambient temperature on the same day as collection.
Transport Instructions
Specimen Stability
24 Hours Room Temperature
Methodology
Whole blood is stimulated with SEB, CMV antigens, or left unstimulated as a negative control and incubated at 37ºC. During the incubation Brefeldin A is added, causing the interferon (IFN)-gamma to be retained inside the cell. Following the stimulation phase, cells are recovered, stained for surface markers (CD3, CD4, CD8, CD69) and intracellular IFN-gamma, and analyzed by flow cytometry. This test has not been cleared or approved for diagnostic use by the U.S. Food and Drug Administration.
